$58M ARPA-H Award Advances Next-Generation Thymic Cell Therapies
$38M
Non-dilutive funding awarded
The human immune system declines with age and can be severely compromised by disease or medical treatments, leaving millions of patients vulnerable and with limited treatment options. Thymmune Therapeutics is advancing a novel approach to immune restoration through a machine learning–powered thymic cell engineering platform. Using iPSC-derived thymic cells, the company is developing scalable, off-the-shelf therapies to rebuild immune function across immunodeficiency, transplant, and autoimmune conditions.
In recognizing the need for substantial capital to bring its technology to the clinic, Thymus reached out to EGC for support in securing non-dilutive funding. Through this partnership, Thymmune was awarded $37M from Advanced Research Projects Agency for Health (ARPA-H) along with NIH funding that has enabled the company to accelerate development of its transformative approach for restoring thymus function.
Alongside the non-dilutive funding, Thymmus has also received $20 million in private investment, and is well on its way to advancing a pipeline of therapies with the potential to transform immune restoration.
“The [EGC] consultants all had significant experience with grant writing and had been able to guide us quickly into the format and other documentary requirements unique to each Grant proposal. Scientific knowledge of the consultants was also excellent enabling significant feedback and contribution to the proposal.”
– Bing Lim, MD, Ph.D, CSO of Thymmune Therapeutics
Funding Sources
